Anti-ApoE antibodies
US11124562B2 · kind B2 · utility
1Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2017 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Oct 27, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure encompasses compositions and methods for effectively treating at least one symptom or sign of A plaque or cerebral amyloid angiopathy (CAA) associated symptoms, or for decreasing amyloid plaque load or CAA load. The method comprises administering an effective amount of an anti-ApoE antibody to a mammalian subject, such as to a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.